Archive: February 10 2021


Immunotherapy Web Featured Images 105

Keytruda Closer to Expanded EU Approval for Pediatric Resistant Hodgkin’s Lympho...

Keytruda (pembrolizumab) has been recommended for approval in the European Union (EU) to treat adults and children, 3 years and older, with relapsed or refractory classical Hodgkin’s lymphoma (cHL) whose disease failed to respond to autologous stem cell transplant (ASCT) or who received at least two prior therapies when ineligible for ASCT.

Visit website
NEWS medical 3

FDA approves cell-based gene therapy to treat adults with relapsed or refractory...

Today, the U.S. Food and Drug Administration approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment.

Visit website